查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1709481

免疫检查点抑制剂市场，按类型、按给药途径、按分布、按应用、按最终用户、按国家和地区 - 2025 年至 2032 年全球行业分析、市场规模、市场份额和预测

Immune Checkpoint Inhibitors Market, By Type, By Route of Administration, By Distribution, By Application, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 322 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

免疫检查点抑制剂市场规模在 2024 年价值 489.839 亿美元，从 2025 年到 2032 年的复合年增长率为 17.60%。

免疫检查点抑制剂市场-市场动态

癌症盛行率的上升和监管部门的批准加速了市场的成长

癌症盛行率的上升和监管部门批准的增加正在加速免疫检查点抑制剂市场的成长。根据世界卫生组织 (WHO) 统计，全球新增癌症病例超过 1,900 万例，推动了对先进免疫疗法的需求。美国 FDA 已批准多种检查点抑制剂，包括 pembrolizumab（Keytruda）和 nivolumab（Opdivo），用于治疗肺癌、黑色素瘤和大肠癌。美国国家癌症研究所 (NCI) 报告称，涉及检查点抑制剂的联合疗法在临床试验中已显示出提高的存活率，这有助于其采用率的提高。此外，政府和研究机构正在大力投资免疫肿瘤学，目前有超过 4,000 项临床试验正在进行中。然而，由于成本高昂，取得药物仍然是一个挑战，因此需要增加生物相似药的开发和价格谈判。随着批准范围的扩大和研究的进展，市场将进一步融入标准癌症治疗。

免疫检查点抑制剂市场—关键见解

根据我们的研究分析师的分析，预测期内（2025-2032 年）全球市场预计年复合成长率约为 17.60%

根据类型细分，预计 PD-1 抑制剂将在 2024 年占据最大市场份额

根据给药途径细分，肠外给药是 2024 年最主要的给药途径

根据分销细分，医院药局是 2024 年的主要分销管道

根据应用细分，肺癌是 2024 年的主要应用

根据最终用户细分，医院和诊所是 2024 年领先的最终用户

按地区划分，北美是 2024 年的主要收入来源

免疫检查点抑制剂市场-細項分析：

全球免疫检查点抑制剂市场根据类型、给药途径、分布、应用、最终用户和地区进行细分。

市场依类型分为三类：PD-1 抑制剂、PD-L1 抑制剂和 CTLA-4 抑制剂。 PD-1 抑制剂因其在多种癌症类型中获得广泛批准且具有强大的临床疗效而占据市场主导地位。 PD-L1 抑制剂紧随其后，在联合疗法中越来越受到关注。 CTLA-4 抑制剂所占份额较小，但在特定癌症治疗中仍然至关重要。

根据给药途径，市场分为两类：口服和肠外给药。肠外给药引领市场，因为大多数免疫检查点抑制剂都是透过静脉输注来达到最佳疗效。口服製剂正在出现但仍然有限。其他方法，包括新颖的交付方法，在不断改进管理技术的研究下占据了一定份额。

免疫检查点抑制剂市场—地理洞察

免疫检查点抑制剂市场正在全球扩张，其中北美由于强大的研究资金、先进的医疗保健基础设施和免疫疗法的广泛采用而处于领先地位。美国 FDA 已批准多种检查点抑制剂，默克、百时美施贵宝和罗氏等主要参与者正在推动创新。欧洲紧随其后，得到欧洲药品管理局 (EMA) 等组织日益增多的监管批准和倡议的支持，以增强癌症治疗的可及性。亚太地区正在经历快速成长，中国和日本大力投资免疫肿瘤学研究和国内药物开发。中国国家药品监督管理局（NMPA）加快了审批速度，促进了本地竞争。在拉丁美洲，医疗保健服务的改善和癌症发病率的上升正在增加需求，但负担能力仍然是一项挑战。在不断扩大的临床试验和国际合作的推动下，中东和非洲正在经历缓慢但稳定的采用，为该地区未来的市场渗透奠定了基础。

免疫检查点抑制剂市场-竞争格局：

免疫检查点抑制剂市场竞争激烈，各大製药公司透过广泛的研发、策略合作和监管部门批准推动创新。默克公司（Keytruda）和百时美施贵宝（Opdivo、Yervoy）凭藉强大的临床试验管道和不断扩大的适应症引领市场。罗氏（Tecentriq）、阿斯特捷利康（Imfinzi）和辉瑞（Bavencio）也是主要参与者，专注于联合疗法以提高疗效。新兴生物技术公司和亚洲製药公司（如百济神州和信达生物）正在透过开发具有成本效益的替代品并扩展到全球市场来加剧竞争。默克与 Moderna 公司在个人化癌症疫苗方面的合作等策略伙伴关係正在进一步塑造这一格局。目前有超过 4,000 项临床试验正在进行中，各公司正在积极探索 LAG-3、TIGIT 和 TIM-3 的下一代检查点抑制剂。定价压力和生物相似药的发展预计将重塑竞争，使可负担性和可及性成为市场扩张的关键因素。

最新动态：

2024 年 12 月，Checkpoint Therapeutics 宣布 FDA 批准 UNLOXCYT(TM) (cosibelimab-ipdl)，这是首个用于治疗晚期皮肤鳞状细胞癌 (cSCC) 的抗 PD-L1 疗法。这是 Checkpoint 首次获得市场批准，为无法接受手术或放射治疗的患者提供差异化治疗选择，有可能改善治疗效果。

2024 年 9 月，OmRx Oncology 启动 OX-4224 的研发，这是一款针对 PD-1/PD-L1 路径的在研口服检查点抑制剂。为了增加全球范围内获得癌症免疫疗法的机会，OmRx 将首先在中低收入国家研究 OX-4224 作为单一疗法，首先在印度针对 NSCLC 进行 2 期试验。

目录

第一章：免疫检查点抑制剂市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 免疫检查点抑制剂市场片段（按类型）
    • 免疫检查点抑制剂市场片段（依给药途径）
    • 免疫检查点抑制剂市场片段（依分布）
    • 免疫检查点抑制剂市场片段（依应用）
    • 免疫检查点抑制剂市场片段（按最终用户）
    • 免疫检查点抑制剂市场（按国家/地区）
    • 免疫检查点抑制剂市场（按地区）
  • 竞争洞察

第三章：免疫检查点抑制剂主要市场趋势

  • 免疫检查点抑制剂市场驱动因素
    • 市场驱动因素的影响分析
  • 免疫检查点抑制剂市场限制
    • 市场限制的影响分析
  • 免疫检查点抑制剂的市场机会
  • 免疫检查点抑制剂市场未来趋势

第四章：免疫检查点抑制剂产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：免疫检查点抑制剂市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：免疫检查点抑制剂市场格局

  • 免疫检查点抑制剂市场份额分析（2024年）
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：免疫检查点抑制剂市场－依类型

  • 概述
    • 按类型分類的细分市场占有率分析
    • PD-1抑制剂
    • PD-L1抑制剂
    • CTLA-4抑制剂
    • 其他的

第 8 章：免疫检查点抑制剂市场 - 按给药途径

  • 概述
    • 按给药途径分類的细分市占率分析
    • 口服
    • 肠外
    • 其他的

第九章：免疫检查点抑制剂市场－依分布

  • 概述
    • 按分布细分市场占有率分析
    • 医院药房
    • 零售药局
    • 网路药局

第 10 章：免疫检查点抑制剂市场 - 按应用

  • 概述
    • 按应用细分市场占有率分析
    • 肺癌
    • 乳癌
    • 膀胱癌
    • 黑色素瘤
    • 子宫颈癌
    • 霍奇金淋巴瘤
    • 大肠直肠癌
    • 其他的

第 11 章：免疫检查点抑制剂市场 - 按最终用户

  • 概述
    • 按最终用户细分的份额分析
    • 医院和诊所
    • 癌症中心
    • 学术和研究机构

第 12 章：免疫检查点抑制剂市场 - 按地区

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美免疫检查点抑制剂主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模和预测（按类型）
    • 北美市场规模及预测（按给药途径）
    • 北美市场规模和预测（按分布）
    • 北美市场规模和预测（按应用）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲免疫检查点抑制剂主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模与预测（按类型）
    • 欧洲市场规模及预测（依管理途径）
    • 欧洲市场规模及预测（按分布）
    • 欧洲市场规模和预测，按应用
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区免疫检查点抑制剂主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区市场规模及预测（按类型）
    • 亚太地区市场规模及预测（依管理途径）
    • 亚太地区市场规模及预测（依分布）
    • 亚太地区市场规模及预测（按应用）
    • 亚太地区市场规模及预测（依最终用户）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲免疫检查点抑制剂主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（按类型）
    • 拉丁美洲市场规模及预测（依管理途径）
    • 拉丁美洲市场规模及预测（依分布）
    • 拉丁美洲市场规模及预测（按应用）
    • LATAM 规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲免疫检查点抑制剂主要製造商
    • 中东和非洲市场规模及预测（按国家/地区）
    • 中东和非洲市场规模和预测（按类型）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模及预测（按分布）
    • 中东和非洲市场规模和预测（按应用）
    • 中东和非洲市场规模及预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 13 章：免疫检查点抑制剂产业关键供应商分析

  • 竞争仪錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • AstraZeneca plc
    • BeiGene, Ltd.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Incyte Corporation
    • Innovent Biologics, Inc.
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Merck & Co., Inc.
    • Novartis International AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Sanofi SA
    • Shanghai Junshi Biosciences Co., Ltd.
    • Tesaro, Inc.
    • Others

第 14 章：360 度分析师视角

第 15 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4954

REPORT HIGHLIGHT

Immune Checkpoint Inhibitors Market size was valued at US$ 48,983.90 Million in 2024, expanding at a CAGR of 17.60% from 2025 to 2032.

The Immune Checkpoint Inhibitors Market focuses on therapies that block checkpoint proteins like PD-1, PD-L1, and CTLA-4 to enhance the immune system's ability to attack cancer cells. Growing cancer prevalence, with over 19 million new cases reported globally in recent years, has accelerated demand for these therapies. Expanding FDA approvals for drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo) across multiple cancer types further fuel market expansion. However, high treatment costs, with some therapies exceeding $150,000 annually per patient, and immune-related adverse effects pose challenges. Ongoing research into combination therapies and novel checkpoint targets presents significant growth opportunities, with clinical trials increasing by nearly 40% over the past five years. Emerging biopharma players and strategic collaborations are further strengthening innovation in this rapidly evolving sector.

Immune Checkpoint Inhibitors Market- Market Dynamics

Expanding cancer prevalence and regulatory approvals accelerating market growth

Expanding cancer prevalence and increasing regulatory approvals are accelerating the growth of the immune checkpoint inhibitors market. According to the World Health Organization (WHO), over 19 million new cancer cases were recorded globally, driving the demand for advanced immunotherapies. The U.S. FDA has approved multiple checkpoint inhibitors, including pembrolizumab (Keytruda) and nivolumab (Opdivo), for treating lung, melanoma, and colorectal cancers. The National Cancer Institute (NCI) reports that combination therapies involving checkpoint inhibitors have shown improved survival rates in clinical trials, contributing to their rising adoption. Additionally, governments and research institutions are investing heavily in immuno-oncology, with over 4,000 clinical trials currently underway. However, access remains a challenge due to high costs, leading to increased efforts in biosimilar development and price negotiations. As approvals expand and research progresses, the market is poised for further integration into standard cancer treatments.

Immune Checkpoint Inhibitors Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 17.60% over the forecast period (2025-2032)

Based on Type segmentation, PD-1 Inhibitors were predicted to show maximum market share in the year 2024

Based on Route of Administration segmentation, Parenteral was the leading Route of Administration in 2024

Based on distribution segmentation, Hospital Pharmacies was the leading distribution in 2024

Based on Application segmentation, Lung Cancer was the leading Application in 2024

Based on end user segmentation, Hospitals & Clinics was the leading end user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Immune Checkpoint Inhibitors Market- Segmentation Analysis:

The Global Immune Checkpoint Inhibitors Market is segmented on the basis of Type, Route of Administration, Distribution, Application, End User, and Region.

The market is divided into three categories based on Type: PD-1 Inhibitors, PD-L1 Inhibitors, and CTLA-4 Inhibitors. PD-1 Inhibitors dominate the market due to their broad approvals across multiple cancer types and strong clinical efficacy. PD-L1 Inhibitors follow, gaining traction in combination therapies. CTLA-4 Inhibitors hold a smaller share but remain crucial in specific cancer treatments.

The market is divided into two categories based on Route of Administration: Oral and Parenteral. Parenteral administration leads the market, as most immune checkpoint inhibitors are delivered via intravenous infusion for optimal efficacy. Oral formulations are emerging but remain limited. Others, including novel delivery methods, hold a niche share with ongoing research into improved administration techniques.

Immune Checkpoint Inhibitors Market- Geographical Insights

The Immune Checkpoint Inhibitors Market is expanding globally, with North America leading due to strong research funding, advanced healthcare infrastructure, and widespread adoption of immunotherapies. The U.S. FDA has approved multiple checkpoint inhibitors, and key players like Merck, Bristol-Myers Squibb, and Roche are driving innovation. Europe follows, supported by increasing regulatory approvals and initiatives from organizations like the European Medicines Agency (EMA) to enhance cancer treatment access. Asia-Pacific is experiencing rapid growth, with China and Japan heavily investing in immuno-oncology research and domestic drug development. China's National Medical Products Administration (NMPA) has accelerated approvals, boosting local competition. In Latin America, improving healthcare access and rising cancer incidence are increasing demand, though affordability remains a challenge. The Middle East and Africa are witnessing slow but steady adoption, driven by expanding clinical trials and international collaborations, positioning the region for future market penetration.

Immune Checkpoint Inhibitors Market- Competitive Landscape:

The Immune Checkpoint Inhibitors Market is highly competitive, with major pharmaceutical companies driving innovation through extensive R&D, strategic collaborations, and regulatory approvals. Merck & Co. (Keytruda) and Bristol-Myers Squibb (Opdivo, Yervoy) lead the market with strong clinical trial pipelines and expanding indications. Roche (Tecentriq), AstraZeneca (Imfinzi), and Pfizer (Bavencio) are also key players, focusing on combination therapies to enhance efficacy. Emerging biotech firms and Asian pharmaceutical companies, such as BeiGene and Innovent Biologics, are intensifying competition by developing cost-effective alternatives and expanding into global markets. Strategic partnerships, like Merck's collaboration with Moderna for personalized cancer vaccines, are further shaping the landscape. With over 4,000 ongoing clinical trials, companies are aggressively exploring next-generation checkpoint inhibitors targeting LAG-3, TIGIT, and TIM-3. Pricing pressures and biosimilar development are expected to reshape competition, making affordability and accessibility critical factors in market expansion.

Recent Developments:

In December 2024, Checkpoint Therapeutics announced FDA approval of UNLOXCYT(TM) (cosibelimab-ipdl), the first anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma (cSCC). This marks Checkpoint's first marketing approval, offering a differentiated treatment option with potential for improved outcomes in patients who cannot undergo surgery or radiation.

In September 2024, OmRx Oncology launched to advance OX-4224, an investigational oral checkpoint inhibitor targeting the PD-1/PD-L1 pathway. Aiming to increase access to cancer immunotherapy worldwide, OmRx will initially study OX-4224 as a monotherapy in low and middle-income countries, starting with a Phase 2 trial in India for NSCLC.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AstraZeneca plc
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Innovent Biologics, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Shanghai Junshi Biosciences Co., Ltd.
  • Tesaro, Inc.
  • Others

GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • PD-1 Inhibitors
  • PD-L1 Inhibitors
  • CTLA-4 Inhibitors
  • Others

GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Parenteral
  • Others

GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Lung Cancer
  • Breast Cancer
  • Bladder Cancer
  • Melanoma
  • Cervical Cancer
  • Hodgkin Lymphoma
  • Colorectal Cancer
  • Others

GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals & clinics
  • Cancer centers
  • Academic and research institutes

GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Immune Checkpoint Inhibitors Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Immune Checkpoint Inhibitors Market Snippet by Type
    • 2.1.2. Immune Checkpoint Inhibitors Market Snippet by Route of Administration
    • 2.1.3. Immune Checkpoint Inhibitors Market Snippet by Distribution
    • 2.1.4. Immune Checkpoint Inhibitors Market Snippet by Application
    • 2.1.5. Immune Checkpoint Inhibitors Market Snippet by End User
    • 2.1.6. Immune Checkpoint Inhibitors Market Snippet by Country
    • 2.1.7. Immune Checkpoint Inhibitors Market Snippet by Region
  • 2.2. Competitive Insights

3. Immune Checkpoint Inhibitors Key Market Trends

  • 3.1. Immune Checkpoint Inhibitors Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Immune Checkpoint Inhibitors Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Immune Checkpoint Inhibitors Market Opportunities
  • 3.4. Immune Checkpoint Inhibitors Market Future Trends

4. Immune Checkpoint Inhibitors Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Immune Checkpoint Inhibitors Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Immune Checkpoint Inhibitors Market Landscape

  • 6.1. Immune Checkpoint Inhibitors Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Immune Checkpoint Inhibitors Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 7.1.2. PD-1 Inhibitors
    • 7.1.3. PD-L1 Inhibitors
    • 7.1.4. CTLA-4 Inhibitors
    • 7.1.5. Others

8. Immune Checkpoint Inhibitors Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Parenteral
    • 8.1.4. Others

9. Immune Checkpoint Inhibitors Market - By Distribution

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution, 2024 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Immune Checkpoint Inhibitors Market - By Application

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 10.1.2. Lung Cancer
    • 10.1.3. Breast Cancer
    • 10.1.4. Bladder Cancer
    • 10.1.5. Melanoma
    • 10.1.6. Cervical Cancer
    • 10.1.7. Hodgkin Lymphoma
    • 10.1.8. Colorectal Cancer
    • 10.1.9. Others

11. Immune Checkpoint Inhibitors Market - By End User

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
    • 11.1.2. Hospitals & clinics
    • 11.1.3. Cancer centers
    • 11.1.4. Academic and research institutes

12. Immune Checkpoint Inhibitors Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Immune Checkpoint Inhibitors Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Immune Checkpoint Inhibitors Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Immune Checkpoint Inhibitors Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Immune Checkpoint Inhibitors Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Immune Checkpoint Inhibitors Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Immune Checkpoint Inhibitors Industry

  • 13.1. Competitive Dashboard
    • 13.1.1. Competitive Benchmarking
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. AstraZeneca plc
    • 13.2.2. BeiGene, Ltd.
    • 13.2.3. Bristol-Myers Squibb Company
    • 13.2.4. Eli Lilly and Company
    • 13.2.5. F. Hoffmann-La Roche Ltd.
    • 13.2.6. GlaxoSmithKline plc
    • 13.2.7. Incyte Corporation
    • 13.2.8. Innovent Biologics, Inc.
    • 13.2.9. Jiangsu Hengrui Medicine Co., Ltd.
    • 13.2.10. Merck & Co., Inc.
    • 13.2.11. Novartis International AG
    • 13.2.12. Pfizer Inc.
    • 13.2.13. Regeneron Pharmaceuticals, Inc.
    • 13.2.14. Sanofi S.A.
    • 13.2.15. Shanghai Junshi Biosciences Co., Ltd.
    • 13.2.16. Tesaro, Inc.
    • 13.2.17. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us